Myriad’s test receives FDA approval as companion diagnostic for Pfizer’s Talzenna

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA has approved BRACAnalysis CDx to be used by healthcare professionals to identify patients with HER2-negative metastatic breast cancer who have a germline BRCA mutation and are eligible for treatment with Pfizer’s PARP inhibitor, Talzenna (talazoparib).

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login